Noxopharm
Australian publicly-listed clinical stage drug development company discovering and developing novel treatments for cancer and inflammation.v.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | AUD2.5m | Post IPO Debt |
| Total Funding | 000k | ||
| AUD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 300 % | 100 % | (25 %) | (17 %) | 20 % | (60 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | 34 % | (115 %) | (367 %) | (247 %) | (148 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (3 %) | (156 %) | (373 %) | (251 %) | (149 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 92 % | - | 156 % | 177 % | 122 % |
Source: Company filings or news article
Related Content
Noxopharm is an Australian publicly listed clinical-stage drug development company, specializing in pioneering therapies for cancer and chronic inflammatory diseases. Founded in 2015, the company operates in the biotechnology sector, focusing on unmet medical needs. Its lead drug candidate, Veyonda, is designed to enhance the effectiveness and safety of chemotherapy and immunotherapy. Veyonda is currently undergoing multiple clinical trials for various types of solid tumors and is also being tested for its potential in treating septic shock and COVID-19 patients at risk. Noxopharm primarily serves healthcare providers, research institutions, and pharmaceutical companies. The company generates revenue through licensing agreements, research grants, and potential future sales of its drug candidates.
Keywords: biotechnology, cancer treatment, immunotherapy, chemotherapy enhancement, clinical trials, drug development, Veyonda, septic shock, chronic inflammation, Australian company.